Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer

Glenwood E. Trivers, Virna M G De Benedetti, Helen L. Cawley, Gail Caron, Anita M. Harrington, William P. Bennett, James R. Jett, Thomas V. Colby, Henry Tazelaar, Peter Pairolero, Roland D. Miller, Curtis C. Harris

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Serum anti-p53 antibodies (p53-Abs) may be surrogate markers for both p53 alterations and preclinical cancer. Ancillary to a prospective trial to abate progressive development of clinical stages of chronic obstructive pulmonary disease, we conducted a retrospective, nested case-control study. Twenty-three cases were diagnosed with cancer during the trial. Enzyme immunoassay, immunoblotting, and immunoprecipitation were used to detect p53-Abs in serum, immunohistochemistry (IHC) to detect p53 accumulation, and single-strand conformation polymorphism and DNA sequencing to detect p53 mutations in tumor samples. p53-Abs were detected by three types of assays in five (23% ) of the cancer patients, 80% of whom had detectable p53-Abs before diagnosis: 2 lung cancers (7 and 6 months before), 1 prostate cancer (11 months), and 1 breast cancer (5 months). Four Ab-positive patients had IHC-positive tumors. Two of 4 Ab-positive patients and 2 of 14 Ab-negative had p53 missense mutations or base pair deletion and IHC-positive tumors. The 44 noncancer COPD controls, matched with the cancer cases for age, gender, and smoking habits, were negative for p53-Abs. These results indicate that p53-Abs may facilitate the early diagnosis of cancer in a subset of smokers with chronic obstructive pulmonary disease who are at an increased cancer risk.

Original languageEnglish (US)
Pages (from-to)1767-1775
Number of pages9
JournalClinical Cancer Research
Volume2
Issue number10
StatePublished - Oct 1996

Fingerprint

Prednisolone
Chronic Obstructive Pulmonary Disease
Anti-Idiotypic Antibodies
Serum
Neoplasms
Antibodies
Immunohistochemistry
Missense Mutation
Immunoenzyme Techniques
DNA Sequence Analysis
Early Detection of Cancer
Immunoprecipitation
Immunoblotting
Base Pairing
Habits
Case-Control Studies
Lung Neoplasms
Prostatic Neoplasms
Biomarkers
Smoking

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Trivers, G. E., De Benedetti, V. M. G., Cawley, H. L., Caron, G., Harrington, A. M., Bennett, W. P., ... Harris, C. C. (1996). Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clinical Cancer Research, 2(10), 1767-1775.

Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. / Trivers, Glenwood E.; De Benedetti, Virna M G; Cawley, Helen L.; Caron, Gail; Harrington, Anita M.; Bennett, William P.; Jett, James R.; Colby, Thomas V.; Tazelaar, Henry; Pairolero, Peter; Miller, Roland D.; Harris, Curtis C.

In: Clinical Cancer Research, Vol. 2, No. 10, 10.1996, p. 1767-1775.

Research output: Contribution to journalArticle

Trivers, GE, De Benedetti, VMG, Cawley, HL, Caron, G, Harrington, AM, Bennett, WP, Jett, JR, Colby, TV, Tazelaar, H, Pairolero, P, Miller, RD & Harris, CC 1996, 'Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer', Clinical Cancer Research, vol. 2, no. 10, pp. 1767-1775.
Trivers GE, De Benedetti VMG, Cawley HL, Caron G, Harrington AM, Bennett WP et al. Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clinical Cancer Research. 1996 Oct;2(10):1767-1775.
Trivers, Glenwood E. ; De Benedetti, Virna M G ; Cawley, Helen L. ; Caron, Gail ; Harrington, Anita M. ; Bennett, William P. ; Jett, James R. ; Colby, Thomas V. ; Tazelaar, Henry ; Pairolero, Peter ; Miller, Roland D. ; Harris, Curtis C. / Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. In: Clinical Cancer Research. 1996 ; Vol. 2, No. 10. pp. 1767-1775.
@article{6ec7e541d44d4e1ab76acd0735982904,
title = "Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer",
abstract = "Serum anti-p53 antibodies (p53-Abs) may be surrogate markers for both p53 alterations and preclinical cancer. Ancillary to a prospective trial to abate progressive development of clinical stages of chronic obstructive pulmonary disease, we conducted a retrospective, nested case-control study. Twenty-three cases were diagnosed with cancer during the trial. Enzyme immunoassay, immunoblotting, and immunoprecipitation were used to detect p53-Abs in serum, immunohistochemistry (IHC) to detect p53 accumulation, and single-strand conformation polymorphism and DNA sequencing to detect p53 mutations in tumor samples. p53-Abs were detected by three types of assays in five (23{\%} ) of the cancer patients, 80{\%} of whom had detectable p53-Abs before diagnosis: 2 lung cancers (7 and 6 months before), 1 prostate cancer (11 months), and 1 breast cancer (5 months). Four Ab-positive patients had IHC-positive tumors. Two of 4 Ab-positive patients and 2 of 14 Ab-negative had p53 missense mutations or base pair deletion and IHC-positive tumors. The 44 noncancer COPD controls, matched with the cancer cases for age, gender, and smoking habits, were negative for p53-Abs. These results indicate that p53-Abs may facilitate the early diagnosis of cancer in a subset of smokers with chronic obstructive pulmonary disease who are at an increased cancer risk.",
author = "Trivers, {Glenwood E.} and {De Benedetti}, {Virna M G} and Cawley, {Helen L.} and Gail Caron and Harrington, {Anita M.} and Bennett, {William P.} and Jett, {James R.} and Colby, {Thomas V.} and Henry Tazelaar and Peter Pairolero and Miller, {Roland D.} and Harris, {Curtis C.}",
year = "1996",
month = "10",
language = "English (US)",
volume = "2",
pages = "1767--1775",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer

AU - Trivers, Glenwood E.

AU - De Benedetti, Virna M G

AU - Cawley, Helen L.

AU - Caron, Gail

AU - Harrington, Anita M.

AU - Bennett, William P.

AU - Jett, James R.

AU - Colby, Thomas V.

AU - Tazelaar, Henry

AU - Pairolero, Peter

AU - Miller, Roland D.

AU - Harris, Curtis C.

PY - 1996/10

Y1 - 1996/10

N2 - Serum anti-p53 antibodies (p53-Abs) may be surrogate markers for both p53 alterations and preclinical cancer. Ancillary to a prospective trial to abate progressive development of clinical stages of chronic obstructive pulmonary disease, we conducted a retrospective, nested case-control study. Twenty-three cases were diagnosed with cancer during the trial. Enzyme immunoassay, immunoblotting, and immunoprecipitation were used to detect p53-Abs in serum, immunohistochemistry (IHC) to detect p53 accumulation, and single-strand conformation polymorphism and DNA sequencing to detect p53 mutations in tumor samples. p53-Abs were detected by three types of assays in five (23% ) of the cancer patients, 80% of whom had detectable p53-Abs before diagnosis: 2 lung cancers (7 and 6 months before), 1 prostate cancer (11 months), and 1 breast cancer (5 months). Four Ab-positive patients had IHC-positive tumors. Two of 4 Ab-positive patients and 2 of 14 Ab-negative had p53 missense mutations or base pair deletion and IHC-positive tumors. The 44 noncancer COPD controls, matched with the cancer cases for age, gender, and smoking habits, were negative for p53-Abs. These results indicate that p53-Abs may facilitate the early diagnosis of cancer in a subset of smokers with chronic obstructive pulmonary disease who are at an increased cancer risk.

AB - Serum anti-p53 antibodies (p53-Abs) may be surrogate markers for both p53 alterations and preclinical cancer. Ancillary to a prospective trial to abate progressive development of clinical stages of chronic obstructive pulmonary disease, we conducted a retrospective, nested case-control study. Twenty-three cases were diagnosed with cancer during the trial. Enzyme immunoassay, immunoblotting, and immunoprecipitation were used to detect p53-Abs in serum, immunohistochemistry (IHC) to detect p53 accumulation, and single-strand conformation polymorphism and DNA sequencing to detect p53 mutations in tumor samples. p53-Abs were detected by three types of assays in five (23% ) of the cancer patients, 80% of whom had detectable p53-Abs before diagnosis: 2 lung cancers (7 and 6 months before), 1 prostate cancer (11 months), and 1 breast cancer (5 months). Four Ab-positive patients had IHC-positive tumors. Two of 4 Ab-positive patients and 2 of 14 Ab-negative had p53 missense mutations or base pair deletion and IHC-positive tumors. The 44 noncancer COPD controls, matched with the cancer cases for age, gender, and smoking habits, were negative for p53-Abs. These results indicate that p53-Abs may facilitate the early diagnosis of cancer in a subset of smokers with chronic obstructive pulmonary disease who are at an increased cancer risk.

UR - http://www.scopus.com/inward/record.url?scp=10244219862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10244219862&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 1767

EP - 1775

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 10

ER -